Systematic Review and Meta-analysis of Tumor Biomarkers in Predicting Prognosis in Esophageal Cancer

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2013 Nov 12

PMID 24206575

Citations 59

Authors

Meilan Chen

Jizheng Huang

Zhenli Zhu

Jun Zhang

Ke Li

Affiliations

Soon will be listed here.

Abstract

Background: Esophageal cancer (EC) is a frequently occurring cancer with poor prognosis despite combined therapeutic strategies. Many biomarkers have been proposed as predictors of adverse events. We sought to assess the prognostic value of biomarkers in predicting the overall survival of esophageal cancer and to help guide personalized cancer treatment to give patients the best chance at remission.

Methods: We conducted a systematic review and meta-analysis of the published literature to summarize evidence for the discriminatory ability of prognostic biomarkers for esophageal cancer. Relevant literature was identified using the PubMed database on April 11, 2012, and conformed to the REMARK criteria. The primary endpoint was overall survival and data were synthesized with hazard ratios (HRs).

Results: We included 109 studies, exploring 13 different biomarkers, which were subjected to quantitative meta-analysis. Promising markers that emerged for the prediction of overall survival in esophageal squamous cell cancer included VEGF (18 eligible studies, n=1476, HR=1.85, 95% CI, 1.55-2.21), cyclin D1 (12 eligible studies, n=1476, HR=1.82, 95% CI, 1.50-2.20), Ki-67 (3 eligible studies, n=308, HR=1.11, 95% CI, 0.70-1.78) and squamous cell carcinoma antigen (5 eligible studies, n=700, HR=1.28, 95% CI, 0.97-1.69); prognostic markers for esophageal adenocarcinoma included COX-2 (2 eligible studies, n=235, HR=3.06, 95% CI, 2.01-4.65) and HER-2 (3 eligible studies, n=291, HR=2.15, 95% CI, 1.39-3.33); prognostic markers for uncategorized ECs included p21 (9 eligible studies, n=858, HR=1.27, 95% CI, 0.75-2.16), p53 (31 eligible studies, n=2851, HR=1.34, 95% CI, 1.21-1.48), CRP (8 eligible studies, n=1382, HR=2.65, 95% CI, 1.64-4.27) and hemoglobin (5 eligible studies, n=544, HR=0.91, 95% CI, 0.83-1.00).

Conclusions: Although some modest bias cannot be excluded, this review supports the involvement of biomarkers to be associated with EC overall survival.

Citing Articles

Combination of neutrophil-to-lymphocyte ratio and albumin concentration to predict the prognosis of esophageal squamous cell cancer patients undergoing esophagectomy.

Lin S, Lin J, Weng J, Su W, Weng G, Chen Y J Thorac Dis. 2023; 15(4):2224-2232.

PMID: 37197552 PMC: 10183513. DOI: 10.21037/jtd-23-333.

The Protease Inhibitor Amprenavir Protects against Pepsin-Induced Esophageal Epithelial Barrier Disruption and Cancer-Associated Changes.

Blaine-Sauer S, Samuels T, Yan K, Johnston N Int J Mol Sci. 2023; 24(7).

PMID: 37047737 PMC: 10095080. DOI: 10.3390/ijms24076765.

Comprehensive analysis of ID genes reveals the clinical and prognostic value of ID3 expression in acute myeloid leukemia using bioinformatics identification and experimental validation.

Zhao Q, Wang Y, Yu D, Leng J, Zhao Y, Chu M BMC Cancer. 2022; 22(1):1229.

PMID: 36443709 PMC: 9707109. DOI: 10.1186/s12885-022-10352-6.

Effect of Ionizing Radiation on the Transcript Variants Expression of p21 Gene.

Danyaei A, Teimoori A, Khanbabaei H, Mansoury Asl H Asian Pac J Cancer Prev. 2021; 22(11):3717-3722.

PMID: 34837932 PMC: 9068170. DOI: 10.31557/APJCP.2021.22.11.3717.

Development and validation of a novel pre-operative comprehensive prognostic score in esophageal squamous cell carcinoma.

Feng J, Wang L, Yang X, Chen Q Bosn J Basic Med Sci. 2021; 22(3):460-470.

PMID: 34676808 PMC: 9162752. DOI: 10.17305/bjbms.2021.6350.

References

Hugo H, Ackland M, Blick T, Lawrence M, Clements J, Williams E . Epithelial--mesenchymal and mesenchymal--epithelial transitions in carcinoma progression. J Cell Physiol. 2007; 213(2):374-83. DOI: 10.1002/jcp.21223. View

Falkenback D, Nilbert M, Oberg S, Johansson J . Prognostic value of cell adhesion in esophageal adenocarcinomas. Dis Esophagus. 2008; 21(2):97-102. DOI: 10.1111/j.1442-2050.2007.00749.x. View

Kuwahara M, Hirai T, Yoshida K, Yamashita Y, Hihara J, Inoue H . p53, p21(Waf1/Cip1) and cyclin D1 protein expression and prognosis in esophageal cancer. Dis Esophagus. 1999; 12(2):116-9. DOI: 10.1046/j.1442-2050.1999.00034.x. View

Yamasaki M, Miyata H, Fujiwara Y, Takiguchi S, Nakajima K, Nishida T . p53 genotype predicts response to chemotherapy in patients with squamous cell carcinoma of the esophagus. Ann Surg Oncol. 2009; 17(2):634-42. DOI: 10.1245/s10434-009-0851-4. View

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

Nishioka K, Doki Y, Shiozaki H, Yamamoto H, Tamura S, Yasuda T . Clinical significance of CDC25A and CDC25B expression in squamous cell carcinomas of the oesophagus. Br J Cancer. 2001; 85(3):412-21. PMC: 2364065. DOI: 10.1054/bjoc.2001.1934. View

Bhandari P, Bateman A, Mehta R, Stacey B, Johnson P, Cree I . Prognostic significance of cyclooxygenase-2 (COX-2) expression in patients with surgically resectable adenocarcinoma of the oesophagus. BMC Cancer. 2006; 6:134. PMC: 1481577. DOI: 10.1186/1471-2407-6-134. View

Merkow R, Bilimoria K, McCarter M, Chow W, Gordon H, Stewart A . Effect of histologic subtype on treatment and outcomes for esophageal cancer in the United States. Cancer. 2011; 118(13):3268-76. DOI: 10.1002/cncr.26608. View

Nozoe T, Korenaga D, Futatsugi M, Saeki H, Maehara Y, Sugimachi K . Immunohistochemical expression of C-reactive protein in squamous cell carcinoma of the esophagus - significance as a tumor marker. Cancer Lett. 2003; 192(1):89-95. DOI: 10.1016/s0304-3835(02)00630-4. View

10.

Yasunaga M, Tabira Y, Kondo K, Okuma T, Kitamura N . The prognostic significance of cell cycle markers in esophageal cancer after neoadjuvant chemotherapy. Dis Esophagus. 1999; 12(2):120-7. DOI: 10.1046/j.1442-2050.1999.00031.x. View

11.

Pomp J, Davelaar J, Blom J, van Krimpen C, Zwinderman A, Quint W . Radiotherapy for oesophagus carcinoma: the impact of p53 on treatment outcome. Radiother Oncol. 1998; 46(2):179-84. DOI: 10.1016/s0167-8140(97)00163-1. View

12.

Yoon M, Nam T, Lee J, Cho S, Song J, Ahn S . VEGF as a predictor for response to definitive chemoradiotherapy and COX-2 as a prognosticator for survival in esophageal squamous cell carcinoma. J Korean Med Sci. 2011; 26(4):513-20. PMC: 3069570. DOI: 10.3346/jkms.2011.26.4.513. View

13.

Kanamoto A, Kato H, Tachimori Y, Watanabe H, Nakanishi Y, Kondo H . No prognostic significance of p53 expression in esophageal squamous cell carcinoma. J Surg Oncol. 1999; 72(2):94-8. DOI: 10.1002/(sici)1096-9098(199910)72:2<94::aid-jso10>3.0.co;2-9. View

14.

Lee M, Yang H . Negative regulators of cyclin-dependent kinases and their roles in cancers. Cell Mol Life Sci. 2002; 58(12-13):1907-22. PMC: 11337304. DOI: 10.1007/pl00000826. View

15.

Kollarova H, Machova L, Horakova D, Janoutova G, Janout V . Epidemiology of esophageal cancer--an overview article. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2007; 151(1):17-20. DOI: 10.5507/bp.2007.003. View

16.

Nozoe T, Ezaki T, Kabashima A, Baba H, Maehara Y . Significance of immunohistochemical expression of cyclooxygenase-2 in squamous cell carcinoma of the esophagus. Am J Surg. 2005; 189(1):110-5. DOI: 10.1016/j.amjsurg.2004.03.019. View

17.

Blanchard P, Quero L, Pacault V, Schlageter M, Baruch-Hennequin V, Hennequin C . Prognostic significance of anti-p53 and anti-KRas circulating antibodies in esophageal cancer patients treated with chemoradiotherapy. BMC Cancer. 2012; 12:119. PMC: 3338390. DOI: 10.1186/1471-2407-12-119. View

18.

Gavin A, Francisci S, Foschi R, Donnelly D, Lemmens V, Brenner H . Oesophageal cancer survival in Europe: a EUROCARE-4 study. Cancer Epidemiol. 2012; 36(6):505-12. DOI: 10.1016/j.canep.2012.07.009. View

19.

Sivula A, Buskens C, van Rees B, Haglund C, Offerhaus G, van Lanschot J . Prognostic role of cyclooxygenase-2 in neoadjuvant-treated patients with squamous cell carcinoma of the esophagus. Int J Cancer. 2005; 116(6):903-8. DOI: 10.1002/ijc.21134. View

20.

Valencia Julve J, Alonso Orduna V, Esco Baron R, Lopez-Mata M, Villamon A . Influence of hemoglobin levels on survival after radical treatment of esophageal carcinoma with radiotherapy. Clin Transl Oncol. 2006; 8(1):22-30. DOI: 10.1007/s12094-006-0091-z. View